RxDoctor Payments Data

Divyesh Bhatt, MD

Interventional Cardiology · Joliet, ILNPI 1043244668

Payments from drug & device makers

$2,043in general payments, 2019–2025

Across 59 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$779
  • E.r. Squibb & Sons, L.L.C.$581
  • Abbott$278
  • AbbVie$124
  • Sanofi-aventis U.S. LLC$122
  • Pfizer$85
  • plus $75 from 3 others

What the payments were for

  • Food & beverage$2,038100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,043 in reported general payments places this provider in the 15th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$337,510
Medicare patients
1,023
Services billed
3,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban608$659,546
XareltoRivaroxaban162$197,522
EntrestoSacubitril/Valsartan70$79,487
Repatha SureclickEvolocumab25$18,749
JardianceEmpagliflozin19$17,699
BrilintaTicagrelor22$16,590
Metoprolol Succinate811$11,620
Pitavastatin Calcium17$9,336
Atorvastatin Calcium383$3,996
Rosuvastatin Calcium315$3,682
Carvedilol386$3,429
Amlodipine Besylate493$3,339
Ezetimibe185$2,927
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$2,502
ClopidogrelClopidogrel Bisulfate156$2,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$659,546608 claims
Johnson & JohnsonXarelto$779$197,522162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Joliet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →